Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
May 15 2023 - 7:00AM
Business Wire
This marks the third consecutive year that
Castle has been recognized with a MedTech Breakthrough Award for
its innovative testing solutions
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it has been selected as the winner of the “Best Use
of Artificial Intelligence in Healthcare” award in the seventh
annual MedTech Breakthrough Awards program for its innovative
TissueCypher® Barrett’s Esophagus test. TissueCypher is Castle’s
risk-stratification test designed to predict future development of
esophageal cancer in patients with Barrett’s esophagus (BE).
BE is a serious complication of gastroesophageal reflux disease
(GERD) and a risk factor for the development of esophageal cancer,
one of the fastest-growing cancers (by incidence) in the U.S., with
a five-year survival rate of less than 20%.1
“Patients with higher grades of BE generally receive effective
interventions, such as ablation therapy, to halt the progression of
BE to esophageal cancer,” said Derek Maetzold, president and chief
executive officer of Castle Biosciences. “However, the majority of
BE patients are graded with lower grades of BE, or as
non-dysplastic. On a population basis, these lower-graded patients
are predicted to have a low likelihood of developing cancer, but
these lower graded patients make up the majority of patients who
end up progressing to esophageal cancer. This disconnect shows
there is a significant clinical need for personalized, biologically
based risk-stratification information to enable improved alignment
between risk of progression and use of effective interventions.
"The personalized risk-stratification information provided by
TissueCypher was discovered, developed and validated to fill this
clinical need, and the harnessing of artificial intelligence was
part of the solution. We are incredibly honored to once again be
recognized with a MedTech Breakthrough Award for our innovation in
testing solutions that guide patient care.”
The TissueCypher test provides clinicians with important
information about a patient’s individual risk of progression to
esophageal cancer based on advanced analysis of biopsied tissue to
guide more informed and risk-aligned management of BE patients.
“Most cancer diagnoses and associated risk-stratification
estimates are currently made by pathologists viewing tissue on
glass slides via light microscopy. This approach is limited in its
ability to evaluate multiple biomarkers and cell types within the
tumor system and predict future development of cancer,” said James
Johnson, managing director, MedTech Breakthrough. “TissueCypher
utilizes artificial intelligence to predict the risk of developing
esophageal cancer – one of the world’s most deadly cancers.
Congratulations to the Castle team on winning the ‘Best Use of
Artificial Intelligence in Healthcare’ award in 2023!”
The mission of the MedTech Breakthrough Awards is to honor
excellence and recognize innovation, hard work and success in a
range of health and medical technology categories. This year’s
program attracted more than 4,000 nominations from over 17
different countries throughout the world.
Castle has previously won two consecutive MedTech Breakthrough
Awards: “Best New Technology Solution — Dermatology” in 2022 for
its DecisionDx®-Melanoma gene expression profile (GEP) test, and
“Best New Technology Solution — Oncology” in 2021 for its
DecisionDx®-SCC and DiffDx®-Melanoma GEP tests.
About TissueCypher® Barrett’s Esophagus Test
The TissueCypher Barrett’s Esophagus test is Castle’s precision
medicine test designed to predict future development of high-grade
dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s
esophagus (BE). TissueCypher is indicated for use in patients with
endoscopic biopsy confirmed BE that is graded non-dysplastic (ND),
indefinite for dysplasia (IND) or low-grade dysplasia (LGD); its
clinical performance has been supported by nine peer-reviewed
publications of BE progressor patients with leading clinical
centers around the world. The TissueCypher Barrett’s Esophagus test
is a proprietary Laboratory Developed Test with its own unique CPT
PLA code (0108U). Additionally, the test received Advanced
Diagnostic Laboratory Test (ADLT) status from the Centers for
Medicare & Medicaid Services (CMS) in March 2022 and was
recognized by the American Gastroenterological Association (AGA) in
their 2022 Clinical Practice Update as a tool that may be used to
risk-stratify patients with NDBE.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME,
DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
Castle Biosciences, Inc.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and
recognition platform for global technology innovation and
leadership, the MedTech Breakthrough Awards program is devoted to
honoring excellence and innovation in medical & health
technology companies, products, services and people. The MedTech
Breakthrough Awards provide a platform for public recognition
around the achievements of breakthrough healthcare and medical
companies and products in categories that include Patient
Experience & Engagement, Health & Fitness, Medical Devices,
Clinical Administration, Connected Healthcare, Medical Data,
Healthcare Cybersecurity and more. For more information, visit
MedTechBreakthrough.com.
1Esophageal Cancer Action Network, https://ecan.org/facts/;
accessed May 12, 2023
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005165/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jul 2023 to Jul 2024